Telo Genomics - TDSGF STOCK NEWS

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has appointed John Farlinger to its Board of Directors, where he will also serve as Chair of the audit committee. Farlinger brings over 30 years of experience in telecom, operations, technology, and finance, currently serving as Assure Neuromonitoring's executive chairman and CEO. He is a Chartered Professional Accountant with a Bachelor of Commerce from Queen's University.

As part of the appointment, the company has granted 850,000 stock options, with 350,000 allocated to Farlinger and 500,000 to a strategic consultant. The options are exercisable at $0.15 per share for five years, vesting immediately with a four-month hold period until August 2, 2025, subject to TSX Venture Exchange approval.

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has announced the appointment of Guido Baechler as Executive Chairman. Baechler, who joined the board in 2019 and became Chairman in 2020, brings over 30 years of life sciences and medical diagnostics experience, including nearly two decades at Roche Diagnostics.

In his expanded role, Baechler will provide active strategic leadership alongside founder Dr. Sabine Mai to advance the company's machine-learning-driven 3D Telomere platform in oncology, focusing on multiple myeloma and prostate cancer. The company's TeloView® platform is designed for clinical laboratory integration, with their CLIA/CAP certified Toronto facility supporting drug development and patient care.

The company also announced board member John Meekison's departure and the non-renewal of former President Sherif Louis's consulting arrangement. Additionally, Telo Genomics has granted 2,460,000 stock options to insiders, employees, and consultants at an exercise price of $0.15 per share with varying terms.

Telo Genomics (TDSGF) has expanded and extended its partnership with Trusted Health Advisors (THA) for a six-month term to advance the commercialization of its diagnostic technologies. The collaboration focuses on:

1. Supporting clinical programs for multiple myeloma (MM) diagnostics, including:

• Identifying high-risk smoldering multiple myeloma patients
• Detecting potential first-line therapy relapse in newly diagnosed MM patients
• Analyzing minimal residual disease cells in post-treated MM patients

2. Expanding into prostate cancer diagnostics, building on previous clinical studies.

As part of the agreement, THA will receive partial compensation in Telo shares, issued in two US$18,000 tranches in March and June 2025, with a maximum of 500,000 shares subject to hold periods.

Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) has announced a non-brokered private placement of units priced at $0.10 each, aiming to raise up to $2,000,000 in gross proceeds. Each unit includes one common share and one non-transferable common share purchase warrant. The warrant allows the holder to purchase an additional common share at $0.15 per share for up to 36 months, with an acceleration clause if the share price reaches $0.40 for ten consecutive trading days. The company may pay finder's fees up to 7% of the gross proceeds and issue finder's warrants equal to 7% of the units sold. The proceeds will be used for general working capital. The securities will be subject to a four-month hold period and are not registered under the United States Securities Act of 1933.

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has received approval for the IPON program, which provides up to CAD 80,000 in IP cost reimbursement plus strategic guidance. The company holds 23 patents (20 granted) covering its TeloView technology across Canada, US, and Europe. Recent patent applications for TeloViewSMM, their flagship product for smoldering multiple myeloma (SMM), would extend protection until 2043. The TeloViewSMM test, clinically validated with Mayo Clinic and Dana Farber Institute, is available as a CLIA laboratory developed test, offering non-invasive risk assessment for SMM patients with an estimated market of over 500,000 tests annually.

Telo Genomics has expanded its collaboration with Mayo Clinic to include participation in their Physician Experience Program SMART, utilizing the TeloViewSMM prognostic test for smoldering multiple myeloma patients. The amendment also covers patient samples for blind validation of TeloViewNDMM, a test for newly diagnosed multiple myeloma patients, as a final step toward adding it as a Laboratory Developed Test. The TeloViewNDMM test aims to identify patients who will relapse on first-line therapy within a year or confirm treatment stability. The collaboration, initiated in 2020, has already led to the successful validation of TeloViewSMM, with results published in the American Journal of Hematology.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has presented new performance data for its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the International Myeloma Society (IMS) 2024 annual meeting. The test outperformed the current 20-2-20 scoring model in identifying both high-risk and low-risk patients in a cohort of 160 SMM patients.

Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the NCCN Myeloma Committee, presented the results. The TeloViewSMM test addresses a critical unmet need in SMM patient management, stratifying patients between high-risk and low-risk progression to full-stage multiple myeloma. This non-invasive liquid biopsy test can be performed using a simple blood draw and used periodically.

The company estimates the total addressable market for TeloViewSMM could result in over 500,000 tests per year, based on recent demographic studies showing SMM prevalence in approximately 0.5% of the population over 40 years old.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) is evaluating its minimal residual disease (MRD) biomarker assay in multiple myeloma patients as part of the TELO-DMRD clinical validation study. The company is collaborating with McGill University and using Adaptive Biotechnologies' clonoSEQ assay to validate the sensitivity of its MRD assay. The study aims to develop two prognostic tests for monitoring myeloma MRD:

1. Identify and quantify MRD cells in blood post marrow transplantation
2. Profile isolated MRD cells using Telo's proprietary TeloView technology

These liquid biopsy-based tests are designed to assess disease aggressiveness in individual MRD cells. The initial evaluation includes up to ten patients, with potential for expansion based on results.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has received CLIA certification from the US Centers for Medicare & Medicaid Services. This important milestone allows Telo to offer its clinical laboratory services within the USA and develop and validate its TeloView prognostic products for distribution in the USA and other international jurisdictions recognizing International CLIA accreditation.

The CLIA certification, combined with the recently achieved CAP accreditation, enables Telo to demonstrate the viability of its TeloView prognostic products to potential US partners. This achievement is expected to advance Telo's platform of prognostic tests across oncology and empower ongoing partnership development efforts with key industry players, particularly in smoldering and minimal residual disease (MRD) in multiple myeloma.